Epigenica’s EpiFinder platform enables simultaneous genome-wide profiling of DNA methylation and histone modifications across diverse sample types. Leveraging multiplex ChIP-seq, it generates up to 192 epigenetic profiles per run, with minimal input material. This scalable approach addresses throughput, cost, and data integration challenges, facilitating drug discovery and precision-medicine research into age-related diseases by uncovering epigenetic biomarkers and mechanisms driving cellular aging.

Key points

• Epigenica secures $2.2M to commercialize EpiFinder high-throughput epigenetic platform.
• EpiFinder Genome performs multiplex ChIP-seq and methylation profiling for eight marks across 24 samples in one run.
• Platform supports diverse input types—cells and tissues—and yields 192 genome-wide profiles per workflow with minimal material.

Why it matters: By enabling multiplexed, scalable epigenomic profiling, researchers can decode aging-related chromatin changes at scale, transforming longevity drug discovery and biomarker development.